38069431|t|Alpha-Lipoic Acid Reduces Cell Growth, Inhibits Autophagy, and Counteracts Prostate Cancer Cell Migration and Invasion: Evidence from In Vitro Studies.
38069431|a|Alpha-lipoic acid (ALA) is a natural antioxidant dithiol compound, exerting antiproliferative and antimetastatic effects in various cancer cell lines. In our study, we demonstrated that ALA reduces the cell growth of prostate cancer cells LNCaP and DU-145. Western blot results revealed that in both cancer cells, ALA, by upregulating pmTOR expression, reduced the protein content of two autophagy initiation markers, Beclin-1 and MAPLC3. Concomitantly, MTT assays showed that chloroquine (CQ) exposure, a well-known autophagy inhibitor, reduced cells' viability. This was more evident for treatment using the combination ALA + CQ, suggesting that ALA can reduce cells' viability by inhibiting autophagy. In addition, in DU-145 cells we observed that ALA affected the oxidative/redox balance system by deregulating the KEAP1/Nrf2/p62 signaling pathway. ALA decreased ROS production, SOD1 and GSTP1 protein expression, and significantly reduced the cytosolic and nuclear content of the transcription factor Nrf2, concomitantly downregulating p62, suggesting that ALA disrupted p62-Nrf2 feedback loop. Conversely, in LNCaP cells, ALA exposure upregulated both SOD1 and p62 protein expression, but did not affect the KEAP1/Nrf2/p62 signaling pathway. In addition, wound-healing, Western blot, and immunofluorescence assays evidenced that ALA significantly reduced the motility of LNCaP and DU-145 cells and downregulated the protein expression of TGFbeta1 and vimentin and the deposition of fibronectin. Finally, a soft agar assay revealed that ALA decreased the colony formation of both the prostate cancer cells by affecting the anchorage independent growth. Collectively, our in vitro evidence demonstrated that in prostate cancer cells, ALA reduces cell growth and counteracts both migration and invasion. Further studies are needed in order to achieve a better understanding of the underlined molecular mechanisms.
38069431	0	17	Alpha-Lipoic Acid	Chemical	MESH:D008063
38069431	75	90	Prostate Cancer	Disease	MESH:D011471
38069431	152	169	Alpha-lipoic acid	Chemical	MESH:D008063
38069431	171	174	ALA	Chemical	MESH:D008063
38069431	201	208	dithiol	Chemical	MESH:C004848
38069431	284	290	cancer	Disease	MESH:D009369
38069431	338	341	ALA	Chemical	MESH:D008063
38069431	369	384	prostate cancer	Disease	MESH:D011471
38069431	391	396	LNCaP	CellLine	CVCL:0395
38069431	401	407	DU-145	CellLine	CVCL:0105
38069431	452	458	cancer	Disease	MESH:D009369
38069431	466	469	ALA	Chemical	MESH:D008063
38069431	570	578	Beclin-1	Gene	8678
38069431	606	609	MTT	Chemical	MESH:C070243
38069431	629	640	chloroquine	Chemical	MESH:D002738
38069431	642	644	CQ	Chemical	MESH:D002738
38069431	774	777	ALA	Chemical	MESH:D008063
38069431	780	782	CQ	Chemical	MESH:D002738
38069431	800	803	ALA	Chemical	MESH:D008063
38069431	873	879	DU-145	CellLine	CVCL:0105
38069431	903	906	ALA	Chemical	MESH:D008063
38069431	971	976	KEAP1	Gene	9817
38069431	977	981	Nrf2	Gene	4780
38069431	982	985	p62	Gene	23636
38069431	1005	1008	ALA	Chemical	MESH:D008063
38069431	1019	1022	ROS	Chemical	-
38069431	1035	1039	SOD1	Gene	6647
38069431	1044	1049	GSTP1	Gene	2950
38069431	1158	1162	Nrf2	Gene	4780
38069431	1193	1196	p62	Gene	23636
38069431	1214	1217	ALA	Chemical	MESH:D008063
38069431	1228	1231	p62	Gene	23636
38069431	1232	1236	Nrf2	Gene	4780
38069431	1267	1272	LNCaP	CellLine	CVCL:0395
38069431	1280	1283	ALA	Chemical	MESH:D008063
38069431	1310	1314	SOD1	Gene	6647
38069431	1319	1322	p62	Gene	23636
38069431	1366	1371	KEAP1	Gene	9817
38069431	1372	1376	Nrf2	Gene	4780
38069431	1377	1380	p62	Gene	23636
38069431	1487	1490	ALA	Chemical	MESH:D008063
38069431	1529	1534	LNCaP	CellLine	CVCL:0395
38069431	1539	1545	DU-145	CellLine	CVCL:0105
38069431	1596	1604	TGFbeta1	Gene	7040
38069431	1609	1617	vimentin	Gene	7431
38069431	1640	1651	fibronectin	Gene	2335
38069431	1694	1697	ALA	Chemical	MESH:D008063
38069431	1741	1756	prostate cancer	Disease	MESH:D011471
38069431	1867	1882	prostate cancer	Disease	MESH:D011471
38069431	1890	1893	ALA	Chemical	MESH:D008063
38069431	Negative_Correlation	MESH:D008063	23636
38069431	Negative_Correlation	MESH:D008063	4780
38069431	Negative_Correlation	MESH:D008063	MESH:D011471
38069431	Association	MESH:D008063	9817
38069431	Negative_Correlation	MESH:D008063	2335
38069431	Negative_Correlation	MESH:D008063	2950
38069431	Negative_Correlation	MESH:D008063	7431
38069431	Positive_Correlation	MESH:D008063	6647
38069431	Negative_Correlation	MESH:D008063	8678
38069431	Negative_Correlation	MESH:D008063	7040

